Article
Author: Wan, Yanzhi ; Jiang, Yuting ; Yin, Jun ; Yun, Hong ; Yang, Xinggang ; Tan, Keqin ; Kang, Qianlong ; Xiang, Yu ; Yin, Xiaomeng ; Lei, Zhen ; Long, Zhiwen ; Zhang, Yu ; Zheng, Aiping ; Wei, Yuhao ; He, Chengyuan ; Jing, Xiaofan ; Feng, Lusi ; Xu, Jiayi ; Liang, Xiao ; Li, Guangqi ; Zhao, Yunuo ; Song, Linlin ; Li, Yueyi ; Li, Renwei ; Zhang, Tao ; Ma, Xuelei ; Shi, Hubing ; Lin, Nan ; Tong, Huan ; Jiang, Zedong ; Li, Xiaoyue ; Huang, Juan ; Luo, Qiang
The effect of the serine/glycine-free diet (-SG diet) on colorectal cancer (CRC) remains unclear; meanwhile, programmed death-1 (PD-1) inhibitors are less effective for most CRC patients. Here, we demonstrate that the -SG diet inhibits CRC growth and promotes the accumulation of cytotoxic T cells to enhance antitumor immunity. Additionally, we also identified the lactylation of programmed death-ligand 1 (PD-L1) in tumor cells as a mechanism of immune evasion during cytotoxic T cell-mediated antitumor responses, and blocking the PD-1/PD-L1 signaling pathway is able to rejuvenate the function of CD8+ T cells recruited by the -SG diet, indicating the potential of combining the -SG diet with immunotherapy. We conducted a single-arm, phase I study (ChiCTR2300067929). The primary outcome suggests that the -SG diet is feasible and safe for regulating systemic immunity. Secondary outcomes include patient tolerability and potential antitumor effects. Collectively, our findings highlight the promising therapeutic potential of the -SG diet for treating solid tumors.